Country: Grikkland
Tungumál: enska
Heimild: HMA (Heads of Medicines Agencies)
marbofloxacin 5 mg
Krka d.d.
QJ01MA93
Tablet
marbofloxacin
Cats, Dogs
2012-11-21
Issued: March 2013 AN: 01882/2011 Page 1 of 6 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Marfloquin 5 mg tablets for cats and dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains: ACTIVE SUBSTANCE: Marbofloxacin …….5 mg EXCIPIENTS: For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Tablets. Light brownish yellow, round, biconvex, marble tablets with bevelled edges and with possible dark and white spots, scored on one side. The tablets can be divided into halves. 4. CLINICAL PARTICULARS 4.1 TARGET SPECIES Cats and dogs. 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES Treatment of infections caused by strains of microorganisms susceptible to marbofloxacin. In dogs: skin and soft tissue infections (skinfold pyoderma, impetigo, folliculitis, furunculosis, cellulitis); urinary tract infections (UTI) associated or not with prostatitis or epididymitis; respiratory tract infections. In cats: skin and soft tissue infections (wounds, abscesses, phlegmons); upper respiratory tract infections. Issued: March 2013 AN: 01882/2011 Page 2 of 6 4.3 CONTRAINDICATIONS Do not use in dogs aged less than 12 months, or less than 18 months for exceptionally large breeds of dogs, such as Great Danes, Briard, Bernese, Bouvier and Mastiffs, with a longer growth period. Do not use in cats aged less than 16 weeks. Do not use in animals with known hypersensitivity to marbofloxacin or other (fluoro)quinolones or to any of the excipients of the Lestu allt skjalið